Alkermes (ALKS) Liabilities from Discontinued Operations (2022 - 2023)
Alkermes' (ALKS) quarterly Liabilities from Discontinued Operations came in at $4.5 million in Q4 2023, down 66.46% year-over-year from $13.5 million in Q4 2022, and down 66.46% quarter-over-quarter from $13.5 million in Q4 2022.
Powered by 
Analysis
Alkermes (ALKS) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Alkermes (ALKS) has reported Liabilities from Discontinued Operations for 2 consecutive years, with $4.5 million the latest figure, recorded in Q4 2023.
- On a quarterly basis, Liabilities from Discontinued Operations fell 66.46% year-over-year to $4.5 million in Q4 2023; TTM through Dec 2023 was $4.5 million, a 66.46% decrease from a year earlier, with the FY2023 full-year figure at $4.5 million, down 66.46% from the prior year.
- Liabilities from Discontinued Operations was $4.5 million for Q4 2023 at Alkermes, down from $13.5 million in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at $13.5 million in Q4 2022 and troughed at $4.5 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.68 Bn | 624.92 Bn | 17.26 Bn |
| 2 | AbbVie | 441.40 Bn | 434.83 Bn | 12.70 Bn |
| 3 | Merck | 365.79 Bn | 358.65 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.44 Bn | 258.75 Bn | 11.24 Bn |
| 5 | Pfizer | 158.97 Bn | 147.27 Bn | 10.94 Bn |
| 6 | Sanofi | 52.38 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.09 Bn | 44.09 Bn | - |
| 8 | Incyte | 25.52 Bn | 20.99 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn |
| 10 | Alkermes | 7.56 Bn | 6.90 Bn | 397.90 Mn |